Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes

被引：6

作者：

Bates E.R. ^{[1
]}

机构：

[1] University of Michigan Medical Center, B1-F245 UH, Ann Arbor, MI 48109-0022, Box 0022

来源：

Current Cardiology Reports | 2001年 / 3卷 / 5期

关键词：

Thrombin; Percutaneous Coronary Intervention; Acute Coronary Syndrome; Streptokinase; Abciximab;

D O I：

10.1007/s11886-001-0050-9

中图分类号：

学科分类号：

摘要：

This review focuses on the use of bivalirudin as a replacement anticoagulant for heparin in patients undergoing percutaneous coronary intervention, or who are being treated for unstable angina pectoris, ST-elevation, or non-ST-elevation myocardial infarction. Potential advantages of bivalirudin include a lack of dependence on antithrombin III for anticoagulant activity, the ability to inactivate both fibrin-bound and soluble thrombin, a lack of aggregatory effects on platelets, a predictable anticoagulant response without monitoring, and a wider therapeutic window. Clinical trial results to date suggest that bivlirudin is at least as effective as heparin with superior safety due to lower bleeding rates. Copyright © 2001 by Current Science Inc..

引用

页码：348 / 354

页数：6

共 41 条

[1]

Kleiman N.S., Weitz J.I., Putting heparin into perspective: Its history and the evolution of its use during percutaneous coronary interventions, J Invasive Cardiol, 12, (2000)

[2]

Popma J.J., Ohman E.M., Weitz J., Et al., Antithrombin therapy in patients undergoing percutaneous coronary intervention, Chest, 119, (2001)

[3]

Braunwald E., Antman E.M., Beasley J.W., Et al., ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 36, pp. 970-1062, (2000)

[4]

Ryan T.J., Antman E.M., Brooks N.H., Et al., 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 34, pp. 890-911, (1999)

[5]

Greinacher A., Janssens U., Berg G., Et al., Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparininduced thrombocytopenia, Circulation, 100, pp. 587-593, (1999)

[6]

Lewis B.E., Wallis D.E., Berkowitz S.D., Et al., Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia, Circulation, 103, pp. 1838-1843, (2001)

[7]

Bates S.M., Weitz J.I., Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin, Am J Cardiol, 82, (1998)

[8]

Bates S.M., Weitz J.I., The mechanism of action of thrombin inhibitors, J Invasive Cardiol, 12, (2000)

[9]

Chew D.P., Bhatt D.L., Lincoff A.M., Et al., Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials, Circulation, 103, pp. 961-966, (2001)

[10]

Serruys P.W., Jpr H., Simon R., Et al., A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty, N Engl J Med, 333, pp. 757-763, (1995)

← 1 2 3 4 5 →